昌紅科技(300151.SZ):子公司與羅氏診斷在進博會上達成戰略合作
格隆匯11月8日丨昌紅科技(300151.SZ)宣佈,2021年11月8日,公司全資子公司深圳市柏明勝醫療器械有限公司(簡稱“深圳柏明勝”)與Roche Diagnostics International Ltd.、 Roche Diagnostics GmbH、 Roche Diagnostics Operations, Inc.、 Roche Diagnostics(Suzhou) Ltd.(合稱“羅氏診斷全球運營”或“羅氏診斷”)在上海第四屆中國國際進口博覽會上簽訂了《戰略合作框架協議》。
羅氏於1896年在瑞士創立。羅氏集團現在擁有診斷和製藥兩個業務領域,在150多個國家擁有超過10萬名員工。羅氏診斷致力於開發和提供從疾病的早期發現、預防到診斷、監測的創新、高性價比、及時和可靠的診斷系統和解決方案。
公司與羅氏診斷自2020年開始合作,合作領域為精密模具設計製造、自動化裝備、診斷耗材和診斷試劑包裝等高分子材料技術應用。近兩年合作金額持續增加,但總金額及其佔公司醫療業務的比重依然較低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.